2019 Future of Graves Diseases R&D Pipeline Drugs and Companies- Analysis of Global Graves Diseases Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

January 2019 | 40 pages | ID: 23A5F45A552EN
VPAResearch

Abstracts

The global demand for Graves Diseases treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Graves Diseases pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Graves Diseases pipeline companies from advancing their products into Phase 3 or Phase 4.

Graves Diseases Report Description

The H1 2019 pipeline review report on Graves Diseases pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Graves Diseases pipeline compounds.

The Graves Diseases pipeline guide presents information on all active drugs currently being developed for Graves Diseases. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Graves Diseases pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Graves Diseases drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Graves Diseases product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Graves Diseases pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Graves Diseases pipeline report includes

• An overview of Graves Diseases disease including symptoms, causes, diagnosis and available treatment options is provided.
• Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
• Phase wise count of pipeline compounds
• Company wise list of pipeline compounds
• Mechanism of Action wise pipeline compounds
• For each pipeline product, the following details are provided-
• Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
• Current status of development
• Drug overview
• Mechanism of Action
• Pre-clinical and Clinical Trials

REASONS TO BUY

• The report is designed to help industry executives promote the success and continued growth of their organizations
• Get clear understanding of the entire Graves Diseases pipeline, with details on active projects
• Stay ahead of the competition through comprehensive knowledge of Graves Diseases pipeline progress
• Get in detail information of each product with updated information on each project along with key milestones
• Gain clear insights into the market through in-depth strategic analysis review
• Know the list of companies participating in global Graves Diseases pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
• Get trial information for each pipeline product under development
• Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2. GLOBAL GRAVES DISEASES PIPELINE OVERVIEW

2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Report Guide and Research Methodology

3. EXECUTIVE SUMMARY

3.1 Graves Diseases Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
3.4 Companies involved in Graves Diseases pipeline, H1- 2019
3.5 Mechanism of Action wise Graves Diseases Pipeline Candidates

4. APITOPE INTERNATIONAL NV GRAVES DISEASES PIPELINE DETAILS

4.1 Apitope International NV Business Profile
4.2 Apitope International NV Graves Diseases Drug Details
  4.2.1 Drug Snapshot
    4.2.1.1 Originator
    4.2.1.2 Collaborator/Co-Developer
    4.2.1.3 Route of Administration
    4.2.1.4 Orphan Drug/Fast Track/Special Designation
    4.2.1.5 Area
    4.2.1.6 Type of Molecular Entity
4.3 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5. AV7 LTD GRAVES DISEASES PIPELINE DETAILS

5.1 AV7 Ltd Business Profile
5.2 AV7 Ltd Graves Diseases Drug Details
  5.2.1 Drug Snapshot
    5.2.1.1 Originator
    5.2.1.2 Collaborator/Co-Developer
    5.2.1.3 Route of Administration
    5.2.1.4 Orphan Drug/Fast Track/Special Designation
    5.2.1.5 Area
    5.2.1.6 Type of Molecular Entity
5.3 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6. NOVARTIS AG GRAVES DISEASES PIPELINE DETAILS

6.1 Novartis AG Business Profile
6.2 Novartis AG Graves Diseases Drug Details
  6.2.1 Drug Snapshot
    6.2.1.1 Originator
    6.2.1.2 Collaborator/Co-Developer
    6.2.1.3 Route of Administration
    6.2.1.4 Orphan Drug/Fast Track/Special Designation
    6.2.1.5 Area
    6.2.1.6 Type of Molecular Entity
6.3 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7. OMEROS CORP GRAVES DISEASES PIPELINE DETAILS

7.1 Omeros Corp Business Profile
7.2 Omeros Corp Graves Diseases Drug Details
  7.2.1 Drug Snapshot
    7.2.1.1 Originator
    7.2.1.2 Collaborator/Co-Developer
    7.2.1.3 Route of Administration
    7.2.1.4 Orphan Drug/Fast Track/Special Designation
    7.2.1.5 Area
    7.2.1.6 Type of Molecular Entity
7.3 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8. RODOS BIOTARGET GRAVES DISEASES PIPELINE DETAILS

8.1 Rodos BioTarget Business Profile
8.2 Rodos BioTarget Graves Diseases Drug Details
  8.2.1 Drug Snapshot
    8.2.1.1 Originator
    8.2.1.2 Collaborator/Co-Developer
    8.2.1.3 Route of Administration
    8.2.1.4 Orphan Drug/Fast Track/Special Designation
    8.2.1.5 Area
    8.2.1.6 Type of Molecular Entity
8.3 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9. LATEST GRAVES DISEASES DRUG PIPELINE DEVELOPMENTS, 2019

10. APPENDIX

10.1 About Us
10.2 Sources and Methodology
10.3 Contact Information